MMP9 and cholangiocarcinoma: Collectively, these findings highlight tiliacorinine’s strong binding affinities to pivotal cholangiocarcinoma-related targets, including MTOR, SRC, MMP9, and MAPK1, underscoring its potential as a promising multi-target therapeutic candidate.